Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 79-84

  Strock, Christopher J ^a   Park, Jong In ^a   Rosen, D Marc ^a   Ruggeri, Bruce ^c   Denmeade, Samuel R ^a,b,c,d   Ball, Douglas W ^a,b   Nelkin, Barry D ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CEPHALON INC   (United States)

^d CRB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 751; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA REPAIR; DRUG ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; CARBAZOLES; CARCINOMA, MEDULLARY; CDC25 PHOSPHATASE; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ENZYME INHIBITORS; HISTONES; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; S PHASE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 30344439815     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1882     Document Type: Article

References (41)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
2. Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF 1999 The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 16:50-63
3. Petursson SR 1988 Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62:1899-1903
4. Samaan NA, Schultz PN, Hickey RC 1988 Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801-805
5. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T 1996 Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-310
6. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire III WP 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432-436
7. Ponder BAJ 2001 Multiple endocrine neoplasia type 2. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic, molecular basis of inherited disease, 8th Ed. New York: McGraw-Hill; 931-942
8. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745
9. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383
10. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619
11. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94:3330-3335
12. Acton DS, Velthuyzen D, Lips CJ, Hoppener JW 2000 Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19:3121-3125
13. Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M 2000 Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res 60:5254-5260
14. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
15. Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA, Zunino F 2000 Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 85:384-390
16. Cohen MS, Hussain HB, Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-967
17. Cassinelli G, Lanzi C, Pensa T, Gambetta RA, Nasini G, Cuccuru G, Cassinis M, Pratesi G, Polizzi D, Tortoreto M, Zunino F 2000 Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. Biochem Pharmacol 59:1539-1547
18. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62:1077-1082
19. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD 2003 CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63:5559-5563
20. Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA 1997 CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int J Cancer 72:673-679
21. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW 2001 Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61:3200-3205
22. Chou TC, Talalay P 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
23. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadra L, Panariello L, Colantuoni V, Fusco A 1995 Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207:1022-1028
24. Massart C, Gibassier J, Denais A, Genetet N 1998 Effect of PSC 833 on the efficacy of doxorubicin in vitro in a medullary thyroid carcinoma cell line. Anticancer Res 18:2953-2956
25. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Frank M, Schmidberger H, Raue F, Becker W 1997 Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57:5309-5319
26. Stein R, Chen S, Reed L, Richel H, Goldenberg DM 2002 Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer 94:51-61
27. Kraeber-Bodere F, Sai-Maurel C, Campion L, Faivre-Chauvet A, Mirallie E, Cherel M, Supiot S, Barbet J, Chatal JF, Thedrez P 2002 Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 1:267-274
28. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K 2004 Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108:464-472
29. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H 2003 Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 278:21767-21773
30. Thiriet C, Hayes JJ 2005 Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 18:617-622
31. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G, Zhang H, Kohn KW 2003 Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 532:173-203
32. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D 2002 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99:3885-3891
33. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT 1999 Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 59:2395-2401
34. Kaczirek K, Schindl M, Weinhausel A, Scheuba C, Passler C, Prager G, Raderer M, Hamilton G, Mittlbock M, Siegl V, Pfragner R, Niederle B 2004 Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 89:2397-2401
35. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y 1997 Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57:4029-4035
36. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH 2005 The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 280:14349-14355
37. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Bohm BO, Schmid RM 2001 Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 61:4526-4535
38. Segouffin-Cariou C, Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 275:3568-3576
39. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins III JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ 2004 Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499
40. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
41. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E 1997 CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 70:335-340